Massachusetts Startup sRNAlytics Develops Potent Small RNA Biomarker Sequencing Data

August 25, 2017
By Alex Keown, Breaking News Staff

NEEDHAM, Mass. – When it comes to pharmaceutical drug development, biomarkers play a key role as de-risking tools. Biomarkers can reduce the time it takes to develop drugs, as well as reduce the cost of drug discovery by increasing endpoint data. 

This means biomarkers can play a key role in increasing the amount of money a pharma company can earn over the life of a drug patent. David Salzman, founder and chief executive officer of biomarker startup sRNAlytics, said that can translate into millions of dollars for drug companies..